BioinvestGPT

BioinvestGPT ApS · Research use only

NCT06677307 (KRRO-110 in Alpha-1 Antitrypsin Deficiency): BVCT ex-ante prediction vs. reported outcome

On 14 May 2025, BioinvestGPT's BVCT predicted technical success and commercial failure for this trial. The 12 Nov 2025 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically probably significant and commercially insufficient.

Clinical Trial

NCTID
NCT06677307
Acronym
REWRITE
Drug Name
KRRO-110
Drug MoA
LNP-encapsulated ADAR-dependent mRNA single-base modifier
Drug Modality
oligonucleotide
Drug Class
First-In-Class
Therapeutic Area
Cardiovascular Diseases and Nutritional and Metabolic Diseases
Indication
Alpha-1 Antitrypsin Deficiency (AATD)
Human Patients
64
Sponsor
Korro Bio
Phase
Phase 1 Phase 2

Prediction of , index 2023

Prospective Prediction
Prediction Index
2023
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit in FEV1 moderately inferior to WVE006)
Technical Prediction
SUCCESS (statistically significant clinical benefit in lung AAT/NE concentration compared with placebo)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
182 days in advance
Readout Data Interpretation
KRRO110 produced functional protein that hasn’t reached the projected level; so further development has been discontinued for low efficacy
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically probably significant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 1/2a, Single- and Multiple-dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KRRO 110 in Healthy Adult Volunteers and in Adult Participants With Alpha-1 Antitrypsin Deficiency (AATD) (REWRITE)
Phase
Phase 1, Phase 2
Status
Terminated
Enrollment
42
Lead sponsor
Korro Bio, Inc.
Conditions
Alpha-1 Anti-trypsin Deficiency; AATD
Interventions
DRUG: KRRO-110
Design
Randomized · Sequential · Double
Primary purpose
Treatment
Start
2025-01-13
Primary completion
2025-10-31
Completion
2025-12-15
Primary outcomes
  • Safety and Tolerability (From Day 1 to Day 43 in the SAD and from Day 1 to Day 85 in the MAD)

NCT06677307 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials